Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis

• Status: Recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among patients with moderate and severe aortic stenosis in Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/CT).

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic

Criteria

Inclusion Criteria:

• Resident of Southeastern Minnesota (Olmsted, Dodge, Fillmore, Mower, Freeborn, Wabasha, or Steele County)

• Age ≥ 75 years

• Current diagnosis of moderate or severe aortic stenosis by most recent (within 6 months at most) echocardiogram as defined by:

• Moderate AS: 1.0 cm2 < aortic valve area (AVA) ≤ 1.5 cm2

• Severe AS: AVA ≤ 1.0 cm2

Exclusion Criteria:

• Any cardiac surgery or major chest trauma within 4 weeks of PYP scan

• Myocardial infarction within 4 weeks of PYP scan defined by typical angina, EKG changes and significant change in serial troponins. (Note that chronic troponin elevation is extremely common in cardiac amyloidosis).

• Prior or current exposure to Plaquenil (Hydroxychloroquine)